Sort   by:  
 Page size 
MetabolomicsFuzheng Jiedu Xiaoji Formula Enhances Anti-PD-1 Therapy for Hepatocellular Carcinoma by Inhibiting Regulatory T Cell Lipotoxicity

Background: The objective response rate of anti-programmed death receptor 1 (PD-1) immunotherapy in hepatocellular carcinoma (HCC) remains limited. The tumor immunosuppressive microenvironment mediated by regulatory T cells (Tregs) is a key bottleneck. The traditional Chinese medicine (TCM) compo...

2025-12-05 | MTBLS13458 | MetaboLights
UnknownInactivated Sendai virus strain Tianjin, a novel genotype of Sendai virus, inhibits growth of murine colon carcinoma through inducing immune responses and apoptosis.
Not available
S-EPMC3844535 | biostudies-literature
UnknownLuteolin exerts anti-tumour immunity in hepatocellular carcinoma by accelerating CD8+ T lymphocyte infiltration.
Not available
S-EPMC11392827 | biostudies-literature
UnknownAssociation of TNF-α-308G/A, -238G/A, -863C/A, -1031T/C, -857C/T polymorphisms with periodontitis susceptibility: Evidence from a meta-analysis of 52 studies.
Not available
S-EPMC7478382 | biostudies-literature
UnknownComputational Analyses Identified Three Diagnostic Biomarkers Associated With Programmed Cell Death for Lung Adenocarcinoma
Not available
S-EPMC12375862 | biostudies-literature
UnknownCo-expression IL-15 receptor alpha with IL-15 reduces toxicity via limiting IL-15 systemic exposure during CAR-T immunotherapy.
Not available
S-EPMC9516829 | biostudies-literature
UnknownSpecific classification and new therapeutic targets for neuroendocrine prostate cancer: A patient-based, diagnostic study.
Not available
S-EPMC9479159 | biostudies-literature
UnknownConcurrent epidermal growth factor receptor T790M secondary mutation and epithelial-mesenchymal transition in a lung adenocarcinoma patient with EGFR-TKI drug resistance.
Not available
S-EPMC5668506 | biostudies-literature
MetabolomicsSerum metabolomic profiles for distinguishing lung cancer from pulmonary tuberculosis: identification of rapid and noninvasive biomarker

BACKGROUND: Pulmonary tuberculosis (TB) and lung cancer (LC) have similar clinical symptoms and atypical imaging findings which are easily misdiagnosed. There is an urgent need for a noninvasive, rapid and accurate biomarker for distinguishing LC from TB.

METHODS:

2024-01-16 | MTBLS6990 | MetaboLights
UnknownKnowledge, attitudes, and practices toward bioterrorism preparedness among nurses: a cross-sectional study.
Not available
S-EPMC11558894 | biostudies-literature
Sort   by:  
 Page size